<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NITROLINGUAL PUMPSPRAY- nitroglycerinÂ spray, meteredÂ </strong><br>Arbor Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NITROLINGUAL<span class="Sup">Â®</span> PUMPSPRAY safely and effectively. See full prescribing information for NITROLINGUAL PUMPSPRAY.<br><br>NITROLINGUALÂ® PUMPSPRAY (nitroglycerin) lingual spray<br>Initial U.S. Approval: 1997</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Nitrolingual Pumpspray is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> due to <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (<a href="#S1">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>At the onset of an attack, administer onto or under the tongue. Repeat every 5 minutes as needed (<a href="#S2.1">2.1</a>).</li>
<li>Do up to three metered sprays within a 15-minute period. If <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> persists, advise prompt medical attention (<a href="#S2.1">2.1</a>).</li>
<li>May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack (<a href="#S2.1">2.1</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Lingual spray, 400 mcg per spray, available in 60 or 200 metered sprays per container (<a href="#S3">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li> Use of  phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). (<a href="#S4.1">4.1</a>)</li>
<li> Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. (<a href="#S4.2">4.2</a>)</li>
<li> Increased  intracranial pressure. (<a href="#S4.3">4.3</a>)</li>
<li> History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Nitrolingual Pumpspray or to other nitrates or nitrites or any excipient. (<a href="#S4.4">4.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Underline">Tolerance:</span> Excessive use may lead to tolerance. (<a href="#S5.1">5.1</a>) </p>
<p class="Highlighta"><span class="Underline"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span> Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. (<a href="#S5.2">5.2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions occurring at a frequency greater than 2% are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizzinesss</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (<a href="#S6">6</a>).<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Arbor Pharmaceuticals, LLC at 1-866-516-4950 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li> Antihypertensives: Possible additive hypotensive effects. (<a href="#S7.2">7.2</a>)</li>
<li> Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div><div>
<div></div>
<div></div>
</div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Priming</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 PDE-5-Inhibitors and sGC-Stimulators</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-4.4" class="toc">4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.5" class="toc">4.5 <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Circulatory Failure</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Tolerance</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="316428" conceptname="Hypertrophic obstructive cardiomyopathy">Hypertrophic Obstructive Cardiomyopathy</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 PDE-5-Inhibitors and sGC-Stimulators</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Antihypertensives</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Ergotamine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and symptoms, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span></a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Treatment of overdosage</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Nitrolingual Pumpspray is indicated for acute relief of an attack or prophylaxis of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> due to <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended dosage</h2>
<p class="First">Instruct the patient to administer one or two metered sprays (400 mcg of nitroglycerin per spray) at the onset of an attack onto or under the tongue. A spray may be repeated approximately every five minutes as needed. No more than three metered sprays are recommended within a 15-minute period. If the <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> persists<span class="Underline"> after a total of three sprays,</span> advise prompt medical attention. Nitrolingual Pumpspray may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Priming</h2>
<p class="First">The pump must be primed prior to the first use. Each metered spray of Nitrolingual Pumpspray delivers 48 mg of solution containing 400 mcg of nitroglycerin after an initial priming of five sprays. It will remain adequately primed for 6 weeks. If the product is not used within 6 weeks it can be adequately re-primed with one spray. If the product is not used within 3 months it can be adequately re-primed with up to five sprays. There are 60 or 200 metered sprays per bottle. The total number of available doses is dependent, however, on the number of sprays per use (1 or 2 sprays), and the frequency of priming.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First">Instruct patients that during administration, the patient should rest, ideally in the sitting position. Hold the container vertically with the valve head uppermost and the spray orifice as close to the mouth as possible. Spray the dose preferably onto or under the tongue by pressing the grooved-button firmly and the mouth closed immediately after each dose. THE SPRAY SHOULD NOT BE INHALED. The medication should not be expectorated or the mouth rinsed for 5 to 10 minutes following administration. Instruct patients to familiarize themselves with the position of the spray orifice, which can be identified by the finger rest on top of the valve, in order to facilitate orientation for administration at night <span class="Italics">[see <a href="#S17">Patient Information (17)</a>].</span></p>
<p>The amount of liquid remaining in the container should be checked periodically. The transparent container can be used for continuous monitoring of the consumption. With the container upright and level, check to be sure the end of the center tube extends below the level of the liquid. Once fluid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below the level of the center tube, remaining sprays will not deliver intended dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lingual spray, 400 mcg per spray available in either 60 or 200 metered sprays per container.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 PDE-5-Inhibitors and sGC-Stimulators</h2>
<p class="First">Do not use Nitrolingual Pumpspray in patients who are taking PDE-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. Concomitant use can cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>].</span></p>
<p>Do not use Nitrolingual Pumpspray in patients who are taking the soluble guanylate cyclase (sGC) stimulator riociguat. Concomitant use can cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></h2>
<p class="First">Nitrolingual Pumpspray is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">Nitrolingual Pumpspray  may precipitate or aggravate <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and thus should not be used in patients with possible <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (e. g. <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.4"></a><a name="section-4.4"></a><p></p>
<h2>4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Nitrolingual Pumpspray is contraindicated in patients who are allergic to nitroglycerin,  other nitrates or nitrites or any excipient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.5"></a><a name="section-4.5"></a><p></p>
<h2>4.5 <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Circulatory Failure</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span></h2>
<p class="First">Nitrolingual Pumpspray is contraindicated in patients with acute <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span> or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Tolerance</h2>
<p class="First">Excessive use may lead to the development of tolerance. Only the smallest number of doses required for effective relief of the acute <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attack</span> should be used <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, particularly with upright posture, may occur even with small doses of nitroglycerin particularly in patients with <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>, aortic or <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span>, patientswho may be volume-depleted, or are already hypotensive. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> induced by nitroglycerin may be accompanied by paradoxical <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and increased <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Symptoms of severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, perspiration and collapse/<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>) may occur even with therapeutic doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="316428" conceptname="Hypertrophic obstructive cardiomyopathy">Hypertrophic Obstructive Cardiomyopathy</span></h2>
<p class="First">Nitrate therapy may aggravate the angina caused by <span class="product-label-link" type="condition" conceptid="316428" conceptname="Hypertrophic obstructive cardiomyopathy">hypertrophic obstructive cardiomyopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">Nitroglycerin produces dose-related <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, especially at the start of nitroglycerin therapy, which may be severe and persistent but usually subside with continued use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Adverse reactions occurring at a frequency greater than 2% and greater than placebo included: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Nitrolingual Pumpspray and other nitroglycerin drugs. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Neurologic: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></p>
<p><span class="Italics">Dermatologic: </span>cutaneous vasodilation, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span>, exfoliative dermatitits</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">Respiratory: </span>transient <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span></p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>,</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 PDE-5-Inhibitors and sGC-Stimulators</h2>
<p class="First">Nitrolingual Pumpspray is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). PDE5 inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</p>
<p>Do not use Nitrolingual Pumpspray in patients who are taking the soluble guanylate cyclase (sGC) stimulator riociguat. Concomitant use can cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>The time course and dose <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of these interactions have not been studied, and use within a few days of one another cannot be recommended. Appropriate supportive care for the severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has not been studied, but it seems reasonable to treat this as a nitrate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, with elevation of the extremities and with central volume expansion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Antihypertensives</h2>
<p class="First">Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. Marked <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> has been reported when calcium channel blockers and organic nitrates were used concomitantly.</p>
<p>Beta-adrenergic blockers blunt the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, additional hypotensive effects may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Ergotamine</h2>
<p class="First">Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> if this is not possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C â€“ Animal teratology studies have not been conducted with Nitroglycerin Pumpspray. Teratology studies in rats and rabbits, however, were conducted with topically applied nitroglycerin ointment at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively. No toxic effects on dams or fetuses were seen at any dose tested. A <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> study was conducted in the third mating of F0 generation female rats administered dietary nitroglycerin for gestation day 6 to day 15 at dose levels used in the 3-generation reproduction study. In offspring of the high-dose nitroglycerin group, increased incidence of <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernias</span> and decreased hyoid bone ossification were seen. The latter finding probably reflects delayed development rather than a potential teratogenic effect, thus indicating no clear evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> of nitroglycerin. There are no adequate and well-controlled studies in pregnant women. Nitroglycerin should be given to pregnant women only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing mothers</h2>
<p class="First">It is not known whether nitroglycerin is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric use</h2>
<p class="First">Safety and effectiveness of nitroglycerin in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly (greater than or equal to 65 years) and younger (less than 65 years) patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and symptoms, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span></h2>
<p class="First">Nitrate overdosage may result in: severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, persistent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">throbbing headache</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and perspiring skin (later becoming <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and cyanotic), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (possibly with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> and even <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (especially in the upright posture), <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> with <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, initial <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and slow breathing, slow pulse (dicrotic and intermittent), <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with cerebral symptoms of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and moderate <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> followed by <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>, and possibly <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>.</p>
<p>Case reports of clinically significant <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> are rare at conventional doses of organic nitrates. The formation of methemoglobin is dose-related and in the case of genetic abnormalities of hemoglobin that favor methemoglobin formation, even conventional doses of organic nitrates could produce harmful concentrations of methemoglobin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Treatment of overdosage</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is the result of venodilatation and arterial <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, prudent therapy in this situation should be directed toward increase in central fluid volume. No specific antagonist to the vasodilator effects of nitroglycerin is known. Keep the patient recumbent in a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> position and comfortably warm. Passive movement of the extremities may aid venous return. Intravenous infusion of normal saline or similar fluid may also be necessary. Administer oxygen and artificial ventilation, if necessary. If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is present, administration of methylene blue (1% solution), 1-2 mg per kilogram of body weight intravenously, may be required unless the patient is known to have G-6-PD deficiency. If an excessive quantity of Nitrolingual Pumpspray has been recently swallowed gastric lavage may be of use.</p>
<p>As epinephrine is ineffective in reversing the severe hypotensive events associated with overdosage, it is not recommended for resuscitation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Nitroglycerin, an organic nitrate, is a vasodilator which has effects on both arteries and veins. The chemical name for nitroglycerin is 1,2,3-propanetriol trinitrate (C<span class="Sub">3</span>H<span class="Sub">5</span>N<span class="Sub">3</span>O<span class="Sub">9</span>). The compound has a molecular weight of 227.09. The chemical structure is:</p>
<p>CH<span class="Sub">2</span>â€“ONO<span class="Sub">2</span><br>|<br>CHâ€“ONO<span class="Sub">2</span><br>|<br>CH<span class="Sub">2</span>â€“ONO<span class="Sub">2</span></p>
<p>Nitrolingual Pumpspray (nitroglycerin lingual spray 400 mcg) is a metered dose spray containing nitroglycerin. This product delivers nitroglycerin (400 mcg per spray, 60 or 200 metered sprays) in the form of spray droplets onto or under the tongue. Inactive ingredients: medium-chain triglycerides, dehydrated alcohol, medium-chain partial glycerides, peppermint oil, sodium lactate, lactic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of action</h2>
<p class="First">Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This eventually leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of the postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and arterial pressure (after load), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear.</p>
<p>Therapeutic doses of nitroglycerin may reduce systolic, diastolic and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> excessively or increased heart rate decreases diastolic filling time.</p>
<p>Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably a reflex response to the <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span> may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>-time index, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressure and increased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> in association with a depressed <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are likely to experience an improvement in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>. In contrast, when filling pressures and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are normal, <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> may be slightly reduced following nitroglycerin administration.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites, 1,2- and 1,3-dinitroglycerin are found in plasma. The mean elimination half-life of both 1,2- and 1,3-dinitroglycerin is about 40 minutes. The 1,2- and 1,3-dinitroglycerin metabolites have been reported to possess some pharmacological activity, whereas the glycerol mononitrate metabolites of nitroglycerin are essentially inactive. Higher plasma concentrations of the dinitro metabolites, with their nearly 8-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect.</p>
<p>In a pharmacokinetic study when a single 0.8 mg dose of Nitrolingual Pumpspray was administered to healthy volunteers (n = 24), the mean C<span class="Sub">max</span> and t<span class="Sub">max</span> were 1.041pg/mL and 7.5 minutes, respectively. Additionally, in these subjects the mean area under the curve (AUC) was 12.769 pg/mL âˆ™ min.</p>
<p>The volume of distribution of nitroglycerin following intravenous administration is 3.3 L/kg.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Drug interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Aspirin</span>: Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Italics">Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (t-PA)</span>: Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenesis studies with sublingual nitroglycerin have not been performed.</p>
<p>Rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidences of hepatocellular carcinomas in both sexes were 52% vs. 0% in controls, and incidences of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice.</p>
<p>Nitroglycerin was weakly mutagenic in Ames tests performed in two different laboratories. There was no evidence of mutagenicity in an <span class="Italics">in vivo</span> dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, p.o., or in <span class="Italics">in vitro</span> cytogenic tests in rat and dog tissues and for chromosomal aberration in Chinese hamster ovary cells.</p>
<p>In a three-generation reproduction study, rats received dietary nitroglycerin at doses up to about 434 mg/kg/day for six months prior to mating of the F<span class="Sub">0</span> generation with treatment continuing through successive F<span class="Sub">1</span> and F<span class="Sub">2</span> generations. The high dose was associated with decreased feed intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in both sexes at all matings. No specific effect on the fertility of the F<span class="Sub">0</span> generation was seen. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males. In this three-generation study there was no clear evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a randomized, double-blind single-dose, 5-period cross-over study in 51 patients with exertional <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> significant dose-related increases in exercise tolerance, time to onset of angina and ST-segment <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were seen following doses of 0.2, 0.4, 0.8 and 1.6 mg of nitroglycerin delivered by metered pumpspray as compared to placebo.</p>
<p>The drug showed a profile of mild to moderate adverse events.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each box of Nitrolingual Pumpspray contains one glass bottle coated with red transparent plastic which assists in containing the glass and medication should the bottle be shattered. Each bottle contains 4.9 g or 14.6 g (Net Content) of nitroglycerin lingual spray which will deliver 60 or 200 metered sprays containing 400 mcg of nitroglycerin per spray after priming.</p>
<p>Nitrolingual Pumpspray is available as:</p>
<ul class="Disc">
<li>60-dose (4.9 g) single bottle NDC 24338-300-65</li>
<li>200-dose (14.6 g) single bottle NDC 24338-300-20</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP Controlled Room Temperature].</p>
<p>Note: Nitrolingual Pumpspray contains 20% alcohol. Do not forcefully open or burn container after use. Do not spray toward flames.</p>
<p>Rx Only.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Instructions for Use)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">The following trademarks are either registered trademarks or trademarks of Pohl-Boskamp in the United States and/or other countries: Pohl-Boskamp word mark; Pohl-Boskamp logo; Nitrolingual word mark; Peppermint flavor of nitroglycerin; Peppermint scent of nitroglycerin; Nitrolingual Pumpspray shapes, Nitrolingual Pumpspray colors, and the sound of Nitrolingual Pumpspray.</p>
<p>U.S. Patent No. 7,872,049</p>
<p>Manufactured for<br>Arbor Pharmaceuticals, LLC Atlanta, GA 30328<br>by G. Pohl-Boskamp GmbH &amp; Co. KG,<br>25551 Hohenlockstedt, Germany.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1>Instructions for Use<br>NitrolingualÂ® Pumpspray (nÄ«-trÅ?-lingÂ´gwal)<br>(nitroglycerin)<br>lingual spray</h1>
<p class="First">Read this Instructions for Use before you start using Nitrolingual Pumpspray and each time you get your prescription refilled. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">Important information:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Nitrolingual Pumpspray is for use onto or under the tongue. </span>Do not inhale Nitrolingual Pumpspray.</li>
<li> A dose of Nitrolingual Pumpspray may be either 1 or 2 sprays. Follow your healthcare provider's instructions about how many sprays you should use for each dose. Doses should be separated by approximately 5 minutes.</li>
<li><span class="Bold">You should not use more than 3 sprays of Nitrolingual Pumpspray within 15 minutes. </span></li>
<li>
<span class="Bold">Get emergency medical help right away if you still have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> after using a total of 3 sprays of Nitrolingual Pumpspray</span>.</li>
</ul>
<p><span class="Bold">Nitrolingual Pumpspray parts:</span></p>
<p><a name="figa"></a><span class="Bold">Figure A</span></p>
<p><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11cb2671-d3d5-425f-8509-f973b6cac876&amp;name=nitrolingual-01.jpg"></p>
<p><span class="Bold">How should I use Nitrolingual Pumpspray?</span></p>
<ul class="Disc">
<li> It is best to use Nitrolingual Pumpspray while you are resting and in a sitting position.</li>
<li>
<span class="Bold">Do not</span> shake the Nitrolingual Pumpspray container.</li>
</ul>
<p><span class="Bold">Priming Nitrolingual Pumpspray:</span></p>
<p>Before you use Nitrolingual Pumpspray for the first time, you must prime it. To prime your Nitrolingual Pumpspray, follow the steps below:</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="8%">
<col align="left" valign="top" width="92%">
<tbody class="Headless"><tr>
<td align="left"><span class="Bold">Step 1.</span></td>
<td align="left">Remove the plastic cap from the container. (See <a href="#figb">Figure B</a>)</td>
</tr></tbody>
</table>
<p><a name="figb"></a>Figure B</p>
<p><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11cb2671-d3d5-425f-8509-f973b6cac876&amp;name=nitrolingual-02.jpg"></p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="8%">
<col align="left" valign="top" width="92%">
<tbody class="Headless"><tr>
<td align="left"><span class="Bold">Step 2.</span></td>
<td align="left">Hold the container upright and facing away from yourself and others. Press down on the top of the grooved button 5 times. (See <a href="#figc">Figure C</a>)</td>
</tr></tbody>
</table>
<p><a name="figc"></a>Figure C</p>
<p><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11cb2671-d3d5-425f-8509-f973b6cac876&amp;name=nitrolingual-03.jpg"></p>
<ul class="Disc">
<li> Your Nitrolingual Pumpspray is now primed. You are ready to give your first dose.</li>
<li> If you do not use your Nitrolingual Pumpspray within 6 weeks, you will need to prime it again by pressing down on the top of the grooved button 1 time.</li>
<li> If you do not use your Nitrolingual Pumpsray within 3 months, you will need to re-prime it by pressing down on the top of the grooved button up to 5 times.</li>
</ul>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="8%">
<col align="left" valign="top" width="92%">
<tbody class="Headless">
<tr><td align="left" colspan="2"><span class="Bold">Giving a dose of Nitrolingual Pumpspray:</span></td></tr>
<tr>
<td align="left"><span class="Bold">Step 3.</span></td>
<td align="left">Hold your Nitrolingual Pumpspray container upright with your index finger on top of the grooved button.</td>
</tr>
<tr>
<td align="left"><span class="Bold">Step 4.</span></td>
<td align="left">Open your mouth and bring the Nitrolingual Pumpspray container as close to your mouth as possible.</td>
</tr>
<tr>
<td align="left"><span class="Bold">Step 5.</span></td>
<td align="left">Press down on the top of the grooved button firmly with your index finger to release the spray onto or under your tongue. (See <a href="#figd">Figure D</a>). The grooved button can help you make sure the canister is turned to the correct position if you are administering the spray in the dark.</td>
</tr>
</tbody>
</table>
<p><a name="figd"></a>Figure D</p>
<p><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11cb2671-d3d5-425f-8509-f973b6cac876&amp;name=nitrolingual-04.jpg"></p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="8%">
<col align="left" valign="top" width="92%">
<tbody class="Headless">
<tr>
<td align="left"><span class="Bold">Step 6.</span></td>
<td align="left">Release the grooved button and close your mouth right away. Avoid swallowing right after using Nitrolingual Pumpspray. Do not spit out Nitrolingual Pumpspray or rinse your mouth for 5 to 10 minutes after using Nitrolingual Pumpspray.</td>
</tr>
<tr>
<td align="left"><span class="Bold">Step 7.</span></td>
<td align="left">If a second dose of Nitrolingual Pumpspray is needed, repeat Steps 3 through 6 above.</td>
</tr>
<tr>
<td align="left"><span class="Bold">Step 8.</span></td>
<td align="left">Replace the plastic cap.</td>
</tr>
</tbody>
</table>
<p>Check the level of the fluid in your Nitrolingual Pumpspray container regularly.</p>
<ul class="Disc">
<li> Check the container in an upright position.</li>
<li> The end of the center tube should be covered by the fluid in the Nitrolingual Pumpspray container. If the level of the fluid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below the end of the center tube, sprays will not provide enough Nitrolingual Pumpspray.</li>
<li> Replace your Nitrolingual Pumpspray container before the fluid level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below the end of the center tube.</li>
</ul>
<p><span class="Bold">How should I store Nitrolingual Pumpspray?</span></p>
<ul class="Disc">
<li> Store Nitrolingual Pumpspray at room temperature 77Â°F (25Â°C); excursions permitted to 59-86Â°F (15-30Â°C).</li>
<li> Do not forcefully open or burn the Nitrolingual Pumpspray container after use.</li>
<li> Do not spray Nitrolingual Pumpspray toward flames.</li>
</ul>
<p><span class="Bold">Keep Nitrolingual Pumpspray and all medicines out of the reach of children</span>.</p>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for Arbor Pharmaceuticals, LLC. Atlanta, GA 30328<br>by G. Pohl-Boskamp GmbH &amp; Co. KG, 25551 Hohenlockstedt, Germany.</p>
<p>Revised: 01/2015</p>
<p>The following trademarks are either registered trademarks or trademarks of Pohl-Boskamp in the United States and / or other countries: Pohl-Boskamp word mark; Pohl-Boskamp logo; Nitrolingual word mark; Peppermint flavor of nitroglycerin; Peppermint scent of nitroglycerin; Nitrolingual Pumpspray shapes, Nitrolingual Pumpspray colors, and the sound of Nitrolingual Pumpspray.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 4.9 g Spray Bottle Carton</h1>
<p class="First"><span class="Bold">Nitrolingual</span><span class="Sup">Â®</span><br>Pumpspray</p>
<p>(nitroglycerin<br>lingual spray)</p>
<p>400 mcg per spray<br>60 Metered Sprays<br>4.9 g Net Contents</p>
<p><span class="Bold">DO NOT SHAKE<br>HOLD CONTAINER UPRIGHT<br>PRIME BEFORE USE</span></p>
<p>NDC 24338-300-65</p>
<p><span class="Bold">arbor</span>â„¢<br>PHARMACEUTICALS, INC.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 4.9 g Spray Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11cb2671-d3d5-425f-8509-f973b6cac876&amp;name=nitrolingual-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NITROLINGUAL PUMPSPRAYÂ 		
					</strong><br><span class="contentTableReg">nitroglycerin spray, metered</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24338-300</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nitroglycerin</strong> (nitroglycerin) </td>
<td class="formItem">nitroglycerin</td>
<td class="formItem">400Â ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>medium-chain triglycerides</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>peppermint oil</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lactate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactic acid</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">PEPPERMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24338-300-65</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24338-300-66</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:24338-300-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">200  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018705</td>
<td class="formItem">02/01/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Arbor Pharmaceuticals, Inc.
							(781796417)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>901b3536-cac1-4218-a1f5-b04fad391918</div>
<div>Set id: 11cb2671-d3d5-425f-8509-f973b6cac876</div>
<div>Version: 7</div>
<div>Effective Time: 20150128</div>
</div>
</div>Â <div class="DistributorName">Arbor Pharmaceuticals, Inc.</div></p>
</body></html>
